Fred Alger Management, LLC Acadia Pharmaceuticals Inc Transaction History

Fred Alger Management, LLC

$19.7 Billion
Q1 2024

A detailed history of Fred Alger Management, LLC transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Fred Alger Management, LLC holds 2,257,564 shares of ACAD stock, worth $35.2 Million. This represents 0.21% of its overall portfolio holdings.

Number of Shares

2,257,564

Previous 3,176,775 28.94%

Holding current value

$35.2 Million

Previous $99.5 Million 58.03%

% of portfolio

0.21%

Previous 0.55%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$17.79 - $30.86 $16.4 Million - $28.4 Million	-919,211 Reduced 28.94%	2,257,564 $41.7 Million
Q4 2023 Feb 14, 2024	BUY	$20.78 - $31.77 $1.41 Million - $2.16 Million	67,892 Added 2.18%	3,176,775 $99.5 Million
Q3 2023 Nov 14, 2023	BUY	$20.84 - $33.47 $18.1 Million - $29 Million	867,818 Added 38.72%	3,108,883 $64.8 Million
Q2 2023 Aug 14, 2023	BUY	$17.8 - $25.65 $9.17 Million - $13.2 Million	515,439 Added 29.87%	2,241,065 $53.7 Million
Q1 2023 May 15, 2023	BUY	$16.32 - $20.92 $4.29 Million - $5.5 Million	262,972 Added 17.98%	1,725,626 $32.5 Million

Q4 2022 Feb 14, 2023	SELL	$14.2 - $18.63 $1.05 Million - $1.38 Million	-74,180 Reduced 4.83%	1,462,654 $23.3 Million
Q3 2022 Nov 14, 2022	SELL	$14.11 - $18.27 $1.2 Million - $1.55 Million	-84,934 Reduced 5.24%	1,536,834 $25.1 Million
Q2 2022 Aug 15, 2022	SELL	$13.01 - $27.22 $1.23 Million - $2.56 Million	-94,169 Reduced 5.49%	1,621,768 $22.9 Million
Q1 2022 May 16, 2022	SELL	$20.94 - $27.5 $2.59 Million - $3.41 Million	-123,916 Reduced 6.74%	1,715,937 $41.6 Million
Q4 2021 Feb 14, 2022	SELL	$16.79 - $27.09 $5.59 Million - $9.02 Million	-333,105 Reduced 15.33%	1,839,853 $42.9 Million
Q3 2021 Nov 15, 2021	SELL	$15.78 - $24.77 $9.95 Million - $15.6 Million	-630,409 Reduced 22.49%	2,172,958 $36.1 Million
Q2 2021 Aug 16, 2021	BUY	$19.4 - $27.42 $331,837 - $469,019	17,105 Added 0.61%	2,803,367 $68.4 Million
Q1 2021 May 17, 2021	BUY	$25.02 - $54.99 $9.87 Million - $21.7 Million	394,420 Added 16.49%	2,786,262 $71.9 Million
Q4 2020 Feb 16, 2021	BUY	$41.04 - $56.79 $12.9 Million - $17.8 Million	313,694 Added 15.09%	2,391,842 $128 Million
Q3 2020 Nov 13, 2020	BUY	$36.42 - $57.0 $31.5 Million - $49.3 Million	864,840 Added 71.28%	2,078,148 $85.7 Million
Q2 2020 Aug 14, 2020	BUY	$39.26 - $52.73 $3.36 Million - $4.51 Million	85,536 Added 7.58%	1,213,308 $58.8 Million
Q1 2020 May 15, 2020	BUY	$31.65 - $46.87 $1.33 Million - $1.97 Million	42,089 Added 3.88%	1,127,772 $47.6 Million
Q4 2019 Feb 14, 2020	BUY	$36.21 - $51.4 $2.84 Million - $4.03 Million	78,469 Added 7.79%	1,085,683 $46.4 Million
Q3 2019 Nov 14, 2019	BUY	$22.22 - $44.01 $4.77 Million - $9.44 Million	214,598 Added 27.07%	1,007,214 $36.3 Million
Q2 2019 Aug 14, 2019	SELL	$23.32 - $28.12 $7.12 Million - $8.59 Million	-305,375 Reduced 27.81%	792,616 $21.2 Million
Q1 2019 May 14, 2019	BUY	$16.17 - $27.38 $586,890 - $993,757	36,295 Added 3.42%	1,097,991 $29.5 Million
Q4 2018 Feb 14, 2019	SELL	$14.32 - $22.92 $765,246 - $1.22 Million	-53,439 Reduced 4.79%	1,061,696 $17.2 Million
Q3 2018 Nov 14, 2018	BUY	$13.03 - $21.81 $2.58 Million - $4.32 Million	198,249 Added 21.62%	1,115,135 $23.2 Million
Q2 2018 Jul 19, 2018	SELL	$15.07 - $22.34 $6.79 Million - $10.1 Million	-450,797 Reduced 32.96%	916,886 $14 Million
Q1 2018 May 10, 2018	SELL	$22.47 - $32.33 $17.9 Million - $25.8 Million	-798,346 Reduced 36.86%	1,367,683 $30.7 Million
Q4 2017 Feb 14, 2018	BUY	$26.84 - $39.14 $4.44 Million - $6.48 Million	165,595 Added 8.28%	2,166,029 $65.2 Million
Q3 2017 Nov 14, 2017	BUY	$29.49 - $38.37 $59 Million - $76.8 Million	2,000,434	2,000,434 $75.4 Million

Others Institutions Holding ACAD

# of Institutions

299

Shares Held

158M

Call Options Held

1.88M

Put Options Held

688K

View Full List

About ACADIA PHARMACEUTICALS INC

Ticker ACAD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 161,843,008
Market Cap $2.52B
Description
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...

More about ACAD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fred Alger Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fred Alger Management, LLC with notifications on news.

Account

Fred Alger Management, LLC Acadia Pharmaceuticals Inc Transaction History